Tags: Drug.
Nivolumab (nye vol’ ue mab) a drug in clinical trials also known as BMS-936558 or MDX1106 is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer. Nivolumab acts as an immunomodulator by blocking ligand activation of the programmed cell death 1 (PD-1) receptor on activated T cells.